Anders Osterborg
Overview
Explore the profile of Anders Osterborg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
5010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Brown J, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al.
Future Oncol
. 2023 Dec;
20(12):717-726.
PMID: 38088119
What Is This Summary About?: This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at...
12.
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Cai C, Gao Y, Adamo S, Rivera-Ballesteros O, Hansson L, Osterborg A, et al.
Sci Immunol
. 2023 Dec;
8(90):eadh0687.
PMID: 38064569
T cells are critical for immune protection against severe COVID-19, but it has remained unclear whether repeated exposure to SARS-CoV-2 antigens delivered in the context of vaccination fuels T cell...
13.
Andersson M, Wu J, Wullimann D, Gao Y, Aberg M, Muschiol S, et al.
J Hematol
. 2023 Sep;
12(4):170-175.
PMID: 37692865
Background: Patients with chronic lymphocytic leukemia (CLL) are vulnerable to coronavirus disease 2019 (COVID-19) and are at risk of inferior response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination,...
14.
Ingelman-Sundberg H, Blixt L, Wullimann D, Wu J, Gao Y, Healy K, et al.
Haematologica
. 2023 Aug;
109(2):646-651.
PMID: 37646668
No abstract available.
15.
Andersson M, Johansson H, Osterborg A, Mansson-Broberg A, Hansson L, Palma M
Eur J Haematol
. 2023 Aug;
111(5):748-756.
PMID: 37565648
Objective: Ibrutinib treatment is associated with cardiovascular side effects, in particular atrial fibrillation (AF) and hypertension, as well as increased risk of bleeding. Here, we aimed at describing the incidence...
16.
Mattsson A, Eketorp Sylvan S, Axelsson P, Ellin F, Kjellander C, Larsson K, et al.
Eur J Haematol
. 2023 Jul;
111(5):715-721.
PMID: 37501508
Objectives: We examined the efficacy and toxicity of the PI3Kδ inhibitor idelalisib in combination with rituximab salvage therapy in consecutively identified Swedish patients with chronic lymphocytic leukemia (CLL). Methods And...
17.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2023 Jul;
94:104700.
PMID: 37453361
Background: Immunocompromised patients have varying responses to SARS-CoV-2 mRNA vaccination. However, there is limited information available from prospective clinical trial cohorts with respect to long-term immunogenicity-related responses in these patient...
18.
Muller T, Sekine T, Trubach D, Niessl J, Chen P, Bergman P, et al.
Sci Transl Med
. 2023 Jul;
15(704):eadg9452.
PMID: 37437015
Suboptimal immunity to SARS-CoV-2 mRNA vaccination has frequently been observed in individuals with various immunodeficiencies. Given the increased antibody evasion properties of emerging SARS-CoV-2 subvariants, it is necessary to assess...
19.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, et al.
J Clin Oncol
. 2023 Jun;
41(21):3689-3699.
PMID: 37279408
Purpose: In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes...
20.
Ghaderi A, Okhovat M, Lehto J, De Petris L, Doulabi E, Kokhaei P, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111634
The ROR1 receptor tyrosine kinase is expressed in embryonic tissues but is absent in normal adult tissues. ROR1 is of importance in oncogenesis and is overexpressed in several cancers, such...